The clinical indications for PET/CT scanning were confirmed or suspected SST-expressing tumors. All patients had undergone surgical resection of the primary NET lesion prior to the imaging studies, and had histopathologically proven grade 1–2 NETs. The 68Ga-DOTA-TATE studies employed the FDA-approved NetSpot™ product. The 68Ga-DOTA-NOC imaging was performed as a clinical procedure under Expanded Access IND #117255. PET/CT image in this study, we analyzed data from 81 patients who underwent routine whole-body 68Ga-DOTA-NOC and/or 68Ga-DOTA-TATE PET/CT (223 scans) to define the location and extent of disease between January 2014 to July 2019 at the Indiana University Health University Hospital, Indianapolis, USA. Inform consent for this retrospective study was waived. The research was approved by the Institutional Review Board at Indiana University in accordance with the Institutional Committee for the Protection of Human Subjects (IRB number: 1411891689). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). We present the following article in accordance with the STROBE reporting checklist (available at ). The purpose of the present study is to assess the interscan variability and reproducibility of significant uptake variability (SUV) metrics in background tissue and NET deposits on 68Ga-DOTA-NOC and 68Ga-DOTA-TATE PET-CT imaging. SSTRs are found in both normal tissue (e.g., liver, spleen, pituitary, adrenal) and sites of disease beyond detection of lesions, it is important to understand whether and how the magnitude of uptake observed in SSTR-targeted PET relates to disease state and therapeutic response ( 5, 17, 20- 22). With the rapid adoption of SSTR-targeted positron emission tomography/computed tomography (PET/CT) imaging into the routine clinical management of NETs, it is necessary to evaluate the accuracy and reliability of interpreting the findings of SSTR-PET/CT imaging, particularly if the diagnostic intention extends beyond definition of sites of disease to an attempt to establish a quantitative measure of total tumor burden based on observed uptake values ( 13- 19). SSTR-targeted probes have become widely utilized across routine clinical contexts for the management of NETs, and open new avenues for precision oncology when paired with a companion receptor-targeted radiotherapeutic agent ( 6- 12). Despite their differences, these tumors share in common a high expression of somatostatin receptors (SSTRs), a property that has been harnessed by recent molecular imaging methods using SSTR analogs ( 5).

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that manifest throughout the body, particularly the gastrointestinal system and lungs ( 1- 4). Keywords: Neuroendocrine tumors (NETs) liver pancreas gastrointestinal tract 68Ga-DOTA PET imaging somatostatin receptors (SSTRs) targeted therapy Highest physiological uptake seen in the spleen (average SUV mean of 17.3, range of 5.4–34.4).Ĭonclusions: The highly variable nature of regional SUV mean and SUV max in both physiologic tissue and lesions suggests the need for incorporation of more reliable quantitative measures for clinical decision making. The adrenal gland showed uptake with SUV max range of 4.1–29.4, which is more than two times greater than liver uptake (SUV mean range, 2.3–12.4). The normal pituitary gland demonstrates focal homogenous uptake with SUV max range of 4.5–23. The median SUV mean was 16 for the spleen, 9.7 for the pituitary, 12.6 for the adrenal glands, and 4.8 for the liver. Results: Both primary and metastatic hepatic lesions demonstrated SUV (SUV mean 16.5☘.0). Eighty-one patients were enrolled in this retrospective study. Methods: We assess the reproducibility and interscan variability of SUV metrics of normal tissue and NET in serial 68Ga-DOTA-NOC and 68Ga-DOTA-TATE PET imaging to clinically monitor disease state. Policy of Dealing with Allegations of Research Misconductīackground: Somatostatin receptor (SSTR)-targeted positron emission tomography/computed tomography (PET/CT) imaging has risen to the forefront for neuroendocrine tumor (NET) detection and management, yet the variability of significant uptake variability (SUV) as a semiquantitative measure of disease detection and tumor response to treatment has not been fully explored.Policy of Screening for Plagiarism Process.

Netspot package insert